| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 79.8 | 71.8 | 75.7 |
| Other income | 1.0 | -0.3 | 0.7 |
| Total income | 80.7 | 71.5 | 76.3 |
| Profit before exceptional items & tax | 1.6 | -1.9 | 0.2 |
| Profit before tax | 1.6 | -1.9 | 0.2 |
| Net profit | 0.9 | -2.0 | -0.2 |
| Operating margin | 2.0% | -2.7% | 0.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +5.40% |
|---|---|
| Operating profit, year on year | +220.00% |
| Operating profit, quarter on quarter | +137.50% |
BSE results filing, NSE: SAMRATPH. Figures extracted from the filing.
Samrat Pharmachem Ltd: key numbers
- Share price
- ₹232.00
- Market cap
- ₹71.68 Cr
- Revenue (annual)
- ₹289.7 Cr
- Net profit (annual)
- ₹-3.31 Cr
- P/E (TTM)
- -32.5×Sector 50.4×
- Promoter holding
- 49.09%+0.00% QoQ
- FII holding
- 3.24%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Samrat Pharmachem Ltd
All →Samrat Pharmachem Board Meeting Date
Samrat Pharmachem will hold a board meeting on November 14, 2026, to consider its unaudited quarterly financial results for the period ended September 2026.
Samrat Pharmachem Other Announcement
Samrat Pharmachem Limited appointed M/s Divyesh J Shah & Associates as Statutory Auditors following the expiry of the previous auditor's tenure at the 34th Annual General Meeting.
Samrat Pharmachem Annual General Meeting
Samrat Pharmachem Limited held its 34th Annual General Meeting on September 23, 2026. The meeting successfully transacted the business items outlined in the prior meeting notice.
Samrat Pharmachem Q4 FY26 Results: Net Loss of ₹2 Cr, Loss Widens
Samrat Pharmachem Ltd reported revenue from operations of ₹71.8 Cr (+0.8% YoY) and a net loss of ₹2 Cr for Q4 FY26.
- Key figure
- Net loss ₹2 Cr